NEW DIRECTOR APPOINTED TO BIOHIT'S DIAGNOSTICS BUSINESS
BIOHIT OYJ STOCK EXCHANGE RELEASE ON 22 JANUARY 2010 AT 3:30 PM
NEW DIRECTOR APPOINTED TO BIOHIT'S DIAGNOSTICS BUSINESS
Yrjö E K Wichmann, MSc. econ., (51), has been appointed Director of Biohit
Oyj's diagnostic business segment as of 1st February 2010.
Prior to joining Biohit, Mr Wichmann has been working for CapMan, most recently
as Funds Raising Director. He has almost 20 years experience from financing and
investment banking, and he has held positions as both Chief Financial Officer
and Equity Capital Markets Director within the healthcare technology industry.
As Director of the diagnostics business, Mr Wichmann reports to the President &
CEO and is member of the Diagnostics Management Team of Biohit Oyj.
Further information:
Osmo Suovaniemi, M.D., Ph.D., Professor
President & CEO
Tel: +358-9-773 861
Email: osmo.suovaniemi@biohit.com
Distribution:
NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com
About Biohit Oyj
Established in 1988, Biohit Oyj is a Finnish biotechnology company quoted on the
NASDAQ OMX Helsinki since 1999. It applies a determined and persistent
innovation and patenting strategy in its operations
(www.biohit.com/Company/History, www.biohit.com/Diagnostics/Literature and
brochures and www.google.com / search “Aggressive innovation and paetenting
stratergy in Finland”)
In cooperation with scientific communities, Biohit produces new technology,
products and services based on research results and innovations for the
development of safe and cost-effective liquid handling in laboratories as well
as the early diagnosis and prevention of gastrointestinal tract diseases
Biohit is divided into liquid handling and diagnostics business units. Liquid
handling products include electronic and mechanical pipettes and dispensers, and
disposable tips, as well as pipette maintenance and calibration services for use
by research institutions, healthcare and industrial laboratories.
The diagnostics business comprises products and analysis systems for the early
detection of gastrointestinal diseases, such as the blood-sample based
GastroPanel and GastroView, for diagnosing diseases of the stomach and
associated risks, quick tests for the diagnosis of lactose intolerance,
Helicobacter pylori infection and ColonView for the early detection of faecal
occult blood. The Acetium capsule, developed to eliminate carcinogenic
acetaldehyde in the gastrointestinal tract, is part of the strategic R&D work of
the diagnostics business unit, whose main objective is the prevention of
gastrointestinal diseases.
Biohit Group employs a staff of approximately 370 in 9 countries. The company is
headquartered in Finland and has subsidiaries in France, Germany, the UK,
Russia, India, China, Japan and the USA. Biohit's products are sold by
approximately 450 distributors in 70 countries.
Biohit's share (BIOBV) is quoted on the NASDAQ OMX Helsinki Small
cap/Healthcare. Read more at www.biohit.com